KOSDAQElectronic Components179290

Mitech

₩2,935▲ 1.03%2026-11-18 close
Market Cap
₩95B
Turnover
₩200M
Volume
70K
Shares out.
32.4M
PER
12.4×
PBR
1.0×
EPS
₩310
Dividend Yield
3.12%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩120 per share · Prices as of the 2026-11-18 close

01

Report overview

Mitech: Record 2025, Q3 2026 Net Loss in Focus

Mitech posted its strongest annual results in the disclosed period in 2025, but its swing to a controlling-shareholder net loss in Q3 2026 makes the durability of its earnings the next test.

  1. 1

    Revenue reached KRW 67.2 billion and operating profit KRW 20.7 billion in 2025, the largest year in the 2022–2025 disclosures.

  2. 2

    Q3 2026 revenue of KRW 18.4 billion rose 8.0% year on year, yet net income attributable to controlling shareholders turned to a loss of KRW 5.75 billion.

  3. 3

    Over the last four quarters, net income attributable to controlling shareholders totaled KRW 10 billion, below the KRW 20.3 billion recorded for full-year 2025.

  4. 4

    Japan and Europe remain the core markets, and the company said North American sales grew about 35% in 2025.

  5. 5

    The debt ratio stood at 12.6% at end-2025, and total equity of KRW 125.9 billion is entirely attributable to controlling shareholders.

02

Business structure

Mitech is a non-vascular stent maker founded in 1991 and listed on KOSDAQ in 2018.

Its core business is gastrointestinal stents used to treat conditions of the bile duct, esophagus, duodenum and colon, which it develops and manufactures in-house and supplies to more than 100 countries across North America, Europe and Asia.

Based on 2022 figures reported by a Korean IR research body, the gastroenterology business accounted for 93% of sales, lithotripter 6% and blood glucose monitoring 1%. In 2023 the company transferred its lithotripter business and stopped manufacturing and selling blood glucose meters, refocusing on gastroenterology.

It holds roughly 3,000 stent designs and has commercialized more than 300 of them for export to major countries at home and abroad. Japan and Europe are the main markets, and in 2025 the company said it rebuilt distribution partnerships by country and expanded supply contracts focused on profitability.

It also said North American sales grew about 35% in 2025 on stronger local marketing despite a limited product range. CE MDR certification in Europe widened from colon and duodenum in September 2023 to the bile duct and bronchi in August 2024 and the esophagus in March 2025.

A Vietnamese subsidiary, wholly owned, was established in Ho Chi Minh City in October 2025. Media reports classify Mitech as one of three leading gastrointestinal stent companies worldwide and describe it as ranked first in market share in Korea and Japan.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩17.1B₩5.7B33.7%
2025Q4———
2026Q1₩16.7B₩4.9B29.4%
2026Q2₩19.8B₩5.8B29.4%
2026Q3₩18.4B₩5B27.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩60.7B₩20.3B₩19.1B33.5%22.9%12.6%
2023₩46.4B₩14.1B₩12.8B30.3%13.8%6.4%
2024₩53.8B₩17.6B₩18.3B32.7%16.8%8.9%
2025₩67.2B₩20.7B₩20.3B30.8%16.1%12.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue fell from KRW 60.7 billion in 2022 to KRW 46.4 billion in 2023, a 23.5% decline, then rose 15.9% to KRW 53.8 billion in 2024 and 24.9% to KRW 67.2 billion in 2025, marking two consecutive years of growth.

Behind the 2023 low, one brokerage analysis points to European sales resuming only after May 2023, and the company classified its lithotripter and blood glucose businesses as discontinued operations in the second half of 2023.

Operating profit was KRW 20.3 billion in 2022, KRW 14.1 billion in 2023 (down 30.8%), KRW 17.6 billion in 2024 (up 25.0%) and KRW 20.7 billion in 2025 (up 17.6%). Operating margin ran at 33.5% in 2022, 30.3% in 2023, 32.7% in 2024 and 30.8% in 2025, staying in the low-to-mid 30s percent range.

The 2025 margin was lower than in 2024, but faster revenue growth lifted absolute operating profit. Net income attributable to controlling shareholders was KRW 19.1 billion in 2022, KRW 12.8 billion in 2023 (down 33.2%), KRW 18.3 billion in 2024 (up 42.9%) and KRW 20.3 billion in 2025 (up 11.2%).

For 2022 through 2024, net income including non-controlling interests was disclosed at KRW 19.1 billion, KRW 12.8 billion and KRW 18.3 billion, the same amounts as attributable net income. On February 25, 2026, the company said revenue and operating profit both set all-time highs since its 1991 founding in 2025.

By quarter, Q3 2025 revenue was KRW 17.1 billion, operating profit KRW 5.75 billion and attributable net income KRW 4.94 billion, followed by Q1 2026 revenue of KRW 16.7 billion, operating profit of KRW 4.91 billion and attributable net income of KRW 4.83 billion.

Q2 2026 revenue rose to KRW 19.8 billion, up 18.1% from the prior quarter, with operating profit of KRW 5.8 billion and attributable net income of KRW 5.83 billion.

Q3 2026 revenue was KRW 18.4 billion, down 6.7% from the prior quarter but up 8.0% year on year, while operating profit was KRW 5.02 billion, down 13.4% quarter on quarter and 12.6% year on year.

The same quarter swung attributable net income to a loss of KRW 5.75 billion, while operating profit stayed positive, so the reason the two lines diverged is the next point to check. Net income attributable to controlling shareholders over the last four quarters totaled KRW 10 billion.

Operating cash flow fell from KRW 8.59 billion in 2022 and KRW 17.8 billion in 2023 to KRW 23.7 billion in 2024 and KRW 14.9 billion in 2025. The debt ratio rose from 6.4% in 2023 to 12.6% in 2025, with total liabilities of KRW 15.9 billion at end-2025.

05

Industry analysis

Mitech belongs to the KOSDAQ medical and precision instruments sector. Demand for stent procedures is rising with global population aging, and next-generation stent technology is being cited as a way to build higher-value markets.

One summary notes the company has been expanding its share of the domestic gastrointestinal endoscopy market. The company developed Korea's first gastrointestinal stent in 1991 and has built non-vascular stent technology for more than 35 years.

It is classified as one of three leading gastrointestinal stent companies worldwide, and media reports describe it as ranked first in market share in the related markets of Korea and Japan. In Japan, strong demand for its multi-hole bile duct product, Multi-Hole, was cited as a main driver of earnings improvement.

A brokerage analysis says research and development spending runs at roughly 8% of sales each year. A 2025 report said the company is preparing to commercialize a new concept stent that releases drugs and biodegrades in the body.

In Europe, expanded CE MDR certification is cited as a way to widen the range of products that can be sold. Demand is generally described as structurally rising with aging populations, and quarterly results depend heavily on sales flow in Europe and Japan.

06

Outlook

The company said it expects external growth in North America, Europe and Asia in 2026, on top of its firm market leadership in Japan.

A corporate monitoring service reported that consolidated revenue in the first half of 2026 rose 10.8% year on year, operating profit fell 0.1% and net income rose 3.8%, based on data as of September 7, 2026.

Q3 2026 revenue rose year on year, but operating profit declined and attributable net income swung to a loss, so whether top-line growth translates into profit is the key question.

North American sales grew about 35% in 2025, but the limited product range is cited as the factor that will determine how fast expansion can proceed. The extension of CE MDR certification to the esophagus in March 2025 widened the range of products the company can sell in Europe.

The Vietnamese subsidiary established in October 2025 is part of expanding overseas production and operations.

Related company Neurobiogen signed a global license and collaboration agreement with a US pharmaceutical company for an oral treatment for dementia, and the synergy expectations attached to it were reported, but how much it will contribute to Mitech consolidated results must be confirmed through periodic filings. The next point to check is the annual operating margin and fourth-quarter figures in the 2026 annual report.

07

Valuation

PER
12.4×
PBR
1.0×
ROE
8.1%
EPS
₩310
BPS
₩3,931
Dividend per share
₩120

Price-to-book sits below the book value of net assets, meaning the share price is trading at a discount to equity rather than at a premium. A corporate monitoring service puts the earnings multiple well below the average of the KOSDAQ medical and precision instruments sector.

The stability of the earnings base that serves as the denominator is the key issue. Full-year 2025 net income attributable to controlling shareholders was KRW 20.3 billion, but the last four quarters total only KRW 10 billion. The Q3 2026 swing to a controlling-shareholder loss accounts for much of that gap.

Operating cash flow fell to KRW 14.9 billion in 2025 from KRW 23.7 billion in 2024, and the debt ratio rose from 6.4% in 2023 to 12.6% in 2025. As a result, what the earnings multiple means depends on whether later quarters restore profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Record-level results in 2025

Revenue reached KRW 67.2 billion and operating profit KRW 20.7 billion in 2025, the largest year in the disclosed 2022–2025 period. The company announced that both metrics set all-time records since its founding. Operating margin held at 30.8%, staying in the 30% range.

Certification and distribution base centered on Japan and Europe

CE MDR certification expanded from colon and duodenum in September 2023 to bile duct, bronchi and esophagus by March 2025. In Japan, strong demand for the Multi-Hole bile duct product is cited as a main earnings driver. Media reports place the company first in market share in Korea and Japan, pointing to a deep regional base.

Low leverage and a second-quarter rebound

The debt ratio was 12.6% at end-2025, with total liabilities of KRW 15.9 billion. Total equity of KRW 125.9 billion is entirely attributable to controlling shareholders. Q2 2026 revenue rose 18.1% from the prior quarter to KRW 19.8 billion, and attributable net income rebounded to KRW 5.83 billion.

09

Bear factors

Swing to a loss in Q3 2026

Q3 2026 revenue of KRW 18.4 billion grew 8.0% year on year, but operating profit fell 12.6% to KRW 5.02 billion. Attributable results swung to a net loss of KRW 5.75 billion. Over the last four quarters, attributable net income totaled KRW 10 billion, below the KRW 20.3 billion recorded for 2025.

Slowing operating cash flow

Operating cash flow fell from KRW 23.7 billion in 2024 to KRW 14.9 billion in 2025. The debt ratio rose from 6.4% in 2023 to 12.6% in 2025 over the same period. Profit grew while the pace of cash generation slowed.

Concentration in regions and distributors, and past business cuts

Gastroenterology accounted for 93% of sales in 2022. In 2023 the company transferred its lithotripter business and stopped blood glucose meter sales. A delay in European MDR recertification in 2023 was cited as causing a gap in European sales. Q1 2026 revenue fell 3.0% year on year.

10

Risk factors

Dependence on regions and distribution partners

Sales are concentrated in Japan and Europe, and the company rebuilt its country-level distribution partnerships in 2025. Sales flows can shift temporarily while distribution structures change. North American sales grew quickly but remain constrained by a limited product range.

Certification and regulatory timing

Expansion in Europe depends on the timing of CE MDR certifications. A 2023 analysis cited a delay in European MDR recertification that left a gap in European sales for January to April. Delays in certification could increase quarterly earnings volatility.

Performance of related companies and overseas subsidiaries

A related company's overseas license agreement raised synergy expectations, but the actual contribution to consolidated results still needs to be confirmed. The Vietnamese subsidiary established in October 2025 is wholly owned, so its early operating costs could affect profit. The effect of subsidiary performance on consolidated margins will need to be checked in periodic filings.

11

What to watch next

  1. December 31, 2026

    This is the end of fiscal 2026. The annual figures disclosed later will include fourth-quarter results, so whether the Q3 swing to a controlling-shareholder loss continued into Q4 is the point to check.

  2. Late February 2027 (estimated)

    Following the pattern of annual results released on February 26, 2025 and February 25, 2026, preliminary 2026 full-year results are expected around this time. These are provisional figures before the periodic report and should be read as such.

  3. End of March 2027

    This is the filing deadline for the 2026 annual report, 90 days after fiscal year-end. Fourth-quarter 2026 figures and the gap between full-year attributable net income and net income including non-controlling interests will be confirmed in the filing.

  4. May 15, 2027

    This is the filing deadline for the Q1 2027 quarterly report, 45 days after quarter-end. It is the first point at which to check whether the Q3 2026 controlling-shareholder loss persists in later quarters.

12

Overall view

Mitech is a specialist gastrointestinal stent company founded in 1991, and after the 2023 low its revenue, operating profit and attributable net income rose for two consecutive years in 2024 and 2025.

Full-year 2025 revenue of KRW 67.2 billion, operating profit of KRW 20.7 billion and attributable net income of KRW 20.3 billion were the largest in the 2022–2025 disclosures. The company said revenue and operating profit both set all-time records in 2025.

However, Q3 2026 revenue rose to KRW 18.4 billion while operating profit fell 12.6% to KRW 5.02 billion, and attributable results swung to a net loss of KRW 5.75 billion.

Strengths include the Japan and Europe distribution base, expanding CE MDR certification and a low debt ratio, while weaknesses include quarterly earnings swings, slower operating cash flow and concentration in regions and distributors.

The share price trades below the book value of net assets, but the recent earnings base in the denominator is lower than the 2025 full-year level, so interpretation depends on whether profit recovers.

The next checkpoints are the 2026 preliminary annual results, the 2026 annual report due by end-March 2027, and the Q1 2027 quarterly report due May 15, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. hankyung.com
  3. businessreport.kr
  4. sks.co.kr
  5. dailyinvest.kr
  6. mt.co.kr
  7. comp.fnguide.com
  8. saramin.co.kr
  9. kr.investing.com
  10. investing.com
  11. comp.wisereport.co.kr
  12. ssl.pstatic.net
  13. investing.com
  14. myasset.com
  15. investing.com
  16. markets.hankyung.com
  17. m.thinkpool.com
  18. jobkorea.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis